Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series

Martínez-García, Sarah Melania; Mota, Sergio E. Hernández-Da; Rubio-Rangel, Araceli; Rojas-Flores, Ignacio; Vieyra-López, Mayra Edith; Martínez-Castellanos, María Ana; Zavala-Martínez, María Teresa; García, Anel Gómez

doi:10.1016/j.circen.2018.01.009

Cited by 3 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this investigation, we found no significant difference between patients receiving IVB and patients without treatment for retinopathy of prematurity. The results of previous research are largely in support of our observations that no substantial association has been observed between intravitreal anti-VEGF and delay in neurodevelopment [ 11 , 15 , 16 , 19 ].…”

Section: Discussionsupporting

confidence: 86%

“…All 7 patients were between 11 to 28 weeks of age, 4 of which showed completely normal scores, 3 of which were presented in high-risk group for neurodevelopmental delay in different cognitive, receptive communication, fine motor and gross motor skills subgroups. At last, they have concluded that we cannot deprive neonates from the favorable effect of anti-VEGF on ROP control and we should not overlook associated diseases in these preterm infants as a confounding factor [ 16 ]. Our findings revealed no major adverse effects of IVB on the long-term neurodevelopmental consequences of premature infants compared to their twin who received no treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Neurodevelopmental Outcomes in Premature Twins (Multigestations) with Retinopathy of Prematurity Receiving Anti-VEGF: A Comparison Study

Ghassemi

Makateb

Farahani

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To assess possible neurodevelopmental delay (NDD) following intravitreal antivascular endothelial growth factor (VEGF) injection in neonates with retinopathy of prematurity (ROP). Methods. In this retrospective cohort study, neurodevelopmental milestones in patients with a history of ROP and intravitreal bevacizumab (IVB) injection were compared with other gestations that received either no treatment or only a laser for treatment. Results. One hundred and twenty-five neonates (of 59 multi-gestation pregnancies) were included in this study (with the range of age 1–7 years old). Sixty-five (51.18%) were male and sixty-two (48.81%) were female. The mean gestational age (GA) and birth weight of all neonates were 29.69 ± 1.57 weeks (ranges: 26–33 weeks) and 1312.50 ± 269.33 grs (ranges: 730–2100 grs). None of the neurodevelopmental outcomes were statistically different when two subgroups in group A (IVB vs. control) were compared. None of the differences between IVB and laser treated subgroups is statistically significant, except for “reaching for toys,” which was delayed in the laser treated subgroup (6.6 ± 2.5 and 6.9 ± 2.5 months in IVB and laser treated subgroups, respectively). Conclusion. In neonates with ROP, there is no linear correlation between intravitreal anti-VEGF injection and neurodevelopmental delay.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Evaluation of Neurodevelopmental Outcomes in Premature Twins (Multigestations) with Retinopathy of Prematurity Receiving Anti-VEGF: A Comparison Study

Ghassemi

Makateb

Farahani

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In our study, normal neurological development was observed in 17 of the 19 infants treated with anti-VEGF; gross motor delay was detected in 2 infants. Martinez-Garcia et al (6) reported that the majority of 7 patients injected with 0.625 mg IVB showed standard neurodevelopmental scores according to the Bayley Scale of Infant Development. In another study of 125 infants in which Morin et al (7) compared the use of laser and bevacizumab, greater odds of neurodevelopmental disabilities were observed in the group treated with bevacizumab at the end of an 18-month period.…”

Section: Discussionmentioning

confidence: 99%

“…The primary purpose of this treatment is to destroy and remove the areas of avascular retina to achieve regression of disease. However, since peripheral ablation causes destruction of a wide area of the retina, especially in zone I disease, new treatment modalities have been investigated (3,(4)(5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular and Systemic Results of Intravitreal Bevacizumab Injection in Retinopathy of Prematurity Treatment

Çevik¹

2020

Beyoglu Eye J

View full text Add to dashboard Cite

The aim of this study was to evaluate the effectiveness and safety of an intravitreal bevacizumab injection (IVB) in the treatment of retinopathy of prematurity (ROP). Methods: The medical records of patients who had received IVB treatment for ROP between January 2014 and October 2018. Anatomical and functional outcomes were evaluated. The Denver II Developmental Screening Test was administered and fluorescein angiography (FA) was performed in some cases. Results: Thirty-eight eyes of 19 infants were included in the study. An IVB injection was administered to 9 infants with aggressive posterior ROP (APROP) disease (Group 1), 6 infants with any stage ROP with plus disease in zone I (Group 2), and 4 infants with stage 2-3 ROP with plus disease in zone II (Group 3). Complete retinal vascularization was observed in 24 eyes of 12 infants who received a single dose of bevacizumab without any additional treatment. Recurrence of the disease was observed in 12 eyes of 6 infants diagnosed with APROP and laser photocoagulation was performed. FA was performed to 5 IVB patients whose parents approved the procedure. The Denver II Developmental Screening Test was administered to all of the participants, and the test outcomes were consistent with the corrected age of the children, though 2 infants demonstrated a developmental delay in gross motor development tasks. Overall, good anatomical and functional results were obtained. Conclusion: IVB is an effective and relatively safe treatment modality for infants with ROP; however, prospective studies are required to provide more detailed information about systemic side effects.

show abstract

Does Anti-Vascular Endothelial Growth Factor Treatment Delay Photoreceptor Maturation in Preterm Infants?

Süren¹,

Küçük²,

Kalaycı³

et al. 2020

OJOph

View full text Add to dashboard Cite

Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series

Cited by 3 publications

References 8 publications

Evaluation of Neurodevelopmental Outcomes in Premature Twins (Multigestations) with Retinopathy of Prematurity Receiving Anti-VEGF: A Comparison Study

Evaluation of Neurodevelopmental Outcomes in Premature Twins (Multigestations) with Retinopathy of Prematurity Receiving Anti-VEGF: A Comparison Study

Ocular and Systemic Results of Intravitreal Bevacizumab Injection in Retinopathy of Prematurity Treatment

Does Anti-Vascular Endothelial Growth Factor Treatment Delay Photoreceptor Maturation in Preterm Infants?

Contact Info

Product

Resources

About